Ligand Pharmaceuticals Inc

Most Recent

  • uploads///pill _
    Healthcare

    Why Ligand Pharmaceuticals Tanked 25%

    Today, US pharmaceutical firm Ligand Pharmaceuticals (LGND) fell 25% from yesterday’s closing price to a low of $98.86 for the day.

    By Jitendra Parashar
  • uploads///LGND
    Company & Industry Overviews

    Key Developments from Ligand’s Partners Bode Well for It

    Ligand Pharmaceuticals (LGND) has key partnerships with Novartis (NVS) for Promacta and Amgen (AMGN) for Kyprolis.

    By Kenneth Smith
  • uploads///LGND
    Company & Industry Overviews

    Analyzing Ligand Pharmaceuticals’ Top Line Trends

    Ligand Pharmaceuticals (LGND) generates revenues from royalties, material sales, license fees, milestone payments, and other sources.

    By Kenneth Smith
  • uploads///bacteria _
    Company & Industry Overviews

    What Analysts Thought of Ligand Pharmaceuticals in June

    Two of the six analysts covering Ligand Pharmaceuticals in June gave the stock “strong buy” ratings, and four gave it “buy” ratings.

    By Kenneth Smith
  • uploads///Graph
    Company & Industry Overviews

    Promacta and Jakavi May Boost Novartis’s Oncology Segment Revenues

    Jakavi reported sales of $228.0 million in 4Q17, which is a year-over-year rise of 33.0% on a constant currency basis.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Analysts Recommend for Alnylam Pharmaceuticals and Peers

    On September 20, 2017, Alnylam Pharmaceuticals (ALNY) announced positive top-line results from phase three trial APOLLO.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    The Medicines Company May Report Steep Revenue Decline in 2017

    In 2Q17, The Medicines Company (MDCO) reported a net loss from continuing operations of $397.3 million, which was a significant fall from $181.8 million in 2Q16.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Analysts’ Recommendations for United Therapeutics

    In 2Q17, United Therapeutics (UTHR) reported revenue of ~$445 million, representing year-over-year growth of around 8%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Analysts Recommend for Acadia Pharmaceuticals in September

    Of the nine analysts covering Acadia Pharmaceuticals in September 2017, two rated the stock a “strong buy,” six rated it a “buy,” and one rated it a “hold.”

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Captisol-Enabled Prexasertib May Be Major Growth Driver for Ligand

    Eli Lilly’s (LLY) Captisol-enabled drug Prexasertib is currently being evaluated in multiple oncology indications such as head and neck cancer, small-cell lung cancer (or SCLC), and advanced metastatic cancer.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Brexanolone Could Strengthen Ligand’s Neurology Portfolio

    Sage Therapeutics is also exploring Brexanolone in moderate and severe post-partum depression (or PPD) patients in two separate Phase 3 trials.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Sparsentan May Be Solid Near-Term Growth Driver for Ligand

    With Sparsentan, Retrophin and Ligand Pharmaceuticals could become major nephrology players similar to peers such as Amgen (AMGN), AstraZeneca (AZN), and Bristol-Myers Squibb (BMY).

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Ligand Pharmaceuticals Projects Higher Average Royalty Rate for Promacta

    Ligand Pharmaceuticals (LGND) receives royalties from Novartis on Promacta’s sales according to a tiered annual payment structure.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Promacta: A Major Growth Driver for Ligand Pharmaceuticals in 2017

    Promacta was discovered by Ligand Pharmaceuticals (LGND) and GlaxoSmithKline (GSK) as a part of their thrombopoietin (or TPO) receptor agonist research collaboration.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Ligand Pharmaceuticals Focuses on Increasing Returns for Shareholders

    Ligand Pharmaceuticals has developed a product portfolio that spans more than 700 patents offering varying degrees of protection to the assets.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Technology Platforms and Research Programs Drive LGND’s Partnerships

    Ligand Pharmaceuticals (LGND) has entered multiple fully funded partnerships by licensing its technology platforms such as OmniAb, Captisol, LTP Technology, and SUREtechnology Platform.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Fully Funded Partnerships May Drive Growth for Ligand Pharmaceuticals

    Ligand Pharmaceuticals (LGND) expects its licensees to invest ~$2.0 billion for advancing more than 155 partnered research and development programs in 2017.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Ligand Pharmaceuticals’ Shots-on-Goal Business Model

    Ligand Pharmaceuticals (LGND) has developed a business model called Shots-on-Goal, which is based on fully funded partnerships.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Ligand Pharmaceuticals Expected to Report Robust Revenue Growth in 2017

    During its 2Q17 earnings conference call, Ligand Pharmaceuticals (LGND) updated its fiscal 2017 revenue guidance from $132 million to $133 million.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Analysts’ Recommendations for Ligand Pharmaceuticals and Peers in 2017

    In 2Q17, Ligand Pharmaceuticals (LGND) reported revenues of ~$28.0 million, representing year-over-year growth of ~43.4%. LGND received ~$14.2 million in royalties, a year-over-year rise of 45.7%.

    By Margaret Patrick
  • uploads///Chart  Keytruda Revenues
    Company & Industry Overviews

    How Did Keytruda Perform in 1Q17?

    Merck (MRK) launched Keytruda in 4Q14 and reported global sales of $584 million for 1Q17. As a result, the company reported ~134% growth in revenues compared to $249 million in 1Q16.

    By Mike Benson
  • uploads///annual revenue projections
    Company & Industry Overviews

    What Is Ligand Pharmaceuticals’s Expected Revenue Growth in 2016?

    Ligand Pharmaceuticals (LGND) is a high-growth company with a comparatively low-risk business model. It earns most of its revenue from royalty and license fees.

    By Jillian Dabney
  • uploads///kyprolis
    Company & Industry Overviews

    Amgen’s Kyprolis with Ligand Pharmaceuticals’s Captisol Technology

    Kyprolis holds a significant 16% market share in proteasome inhibitor–type drugs.

    By Jillian Dabney
  • uploads///Promacta
    Company & Industry Overviews

    How Much Potential Does Promacta Hold?

    On April 2016, Promacta received approval in the EU for treating ITP patients who are one year of age and older.

    By Jillian Dabney
  • uploads///portfolio
    Company & Industry Overviews

    Ligand Pharmaceuticals’s Portfolio Pyramid as Its Valuation Catalyst

    Ligand Pharmaceuticals’s (LGND) product portfolio has expanded from nine programs in 2008 to 140+ programs in 2016.

    By Jillian Dabney
  • uploads///Part  Graph
    Company & Industry Overviews

    Agios Stock Rises on Higher Trading Volumes on June 8

    Three analysts recommended a “buy” for Agios (AGIO), eight analysts recommended a “hold,” and no analysts recommended a “sell” for the stock. Agios has a weight of 2.2% in XBI’s portfolio.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    JPMorgan Upgrades Ophthotech: Stock Skyrockets

    Ophthotech (OPHT) rose 11.6% for the week ended June 3, 2016, and outperformed the SPDR S&P 500 ETF (SPY). It was one of the top mid-cap performers.

    By Peter Neil
  • uploads///Chart
    Company & Industry Overviews

    Ionis Pharmaceuticals: Valuation Compared to Its Peers

    In this series, we’ll be looking at Ionis Pharmaceuticals’ (IONS) products and other factors that drive its revenues. This will give us a better understanding of what drives Ionis’s revenues.

    By Mike Benson
  • uploads///Part  Graph
    Company & Industry Overviews

    IBB Mid-Caps: Medicines Company’s Carbavance, Fast-Track Status

    In a press release, the Medicines Company (MDCO) announced that the FDA has granted fast-track status to Carbavance for the treatment of complicated urinary tract infections.

    By Peter Neil
  • uploads///Chart
    Company & Industry Overviews

    Incyte Continues Its Growth Spree in 2015

    Incyte is a biopharmaceutical company that’s focused on the discovery, development, and commercialization of oncology drugs.

    By Mike Benson
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.